Pharming Group

Pharming Group is a leading biopharmaceutical company that specializes in developing innovative protein replacement therapies and precision medicines for rare diseases. Its flagship product, Ruconest, is a recombinant human C1 inhibitor that has been approved for the treatment of hereditary angioedema (HAE) in the European Union, United States, and other countries. The company is also working on a pipeline of products for the treatment of other rare diseases, such as Pompe disease and Fabry disease. Pharming Group's mission is to enhance the lives of patients with rare diseases by providing them with safe and effective treatments that address the root causes of their conditions. With headquarters in Leiden, the Netherlands, and operations in the United States and Europe, the company is dedicated to advancing the field of biotechnology through research and development, collaboration with academic institutions and industry partners, and the use of cutting-edge technologies.